Healthcare and pharma
LLY vs NVO: AI-Powered Investment Comparison
A structural side-by-side look at Eli Lilly and Company and Novo Nordisk A/S: how each business actually makes money, what could go wrong and which investor profile each name suits best. ARIA Analyst scores both tickers with the same deterministic engine so the comparison stays apples-to-apples.
Side-by-side comparison
| Metric | LLY | NVO |
|---|---|---|
| Market cap | Mega-cap | Mega-cap |
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - General | Drug Manufacturers - General |
| P/E ratio (approx.) | ~40-70x (historical, elevated) | ~25-40x (historical) |
| 1Y range (qualitative) | Upward, GLP-1 driven | Volatile, GLP-1 competition-sensitive |
| ARIA verdict | View live score | View live score |
| Confidence | See ML calibration | See ML calibration |
All figures are qualitative or historical ranges. For dated, live metrics including current price, valuation multiples and ARIA score, open the per-ticker analysis page.
Business overview
Eli Lilly and Company (LLY)
Eli Lilly is a global pharmaceutical company with leading franchises in diabetes (Mounjaro, tirzepatide) and obesity (Zepbound), oncology (Verzenio), immunology and Alzheimer's (donanemab). The GLP-1 franchise has become the dominant earnings driver.
Manufacturing capacity for GLP-1 has been the binding constraint on near-term revenue and remains the focus of capex expansion.
Novo Nordisk A/S (NVO)
Novo Nordisk is the Danish pharmaceutical company behind Ozempic and Wegovy (semaglutide), the GLP-1 franchise that competes directly with Eli Lilly's tirzepatide. The company also has a long-standing leadership position in insulin and a credible obesity-pipeline including CagriSema.
US market dynamics, formulary access and oral GLP-1 progress are the key variables for the next several years.
Why ARIA Analyst flags each as worth a closer look
LLY: structural strengths
Best-in-class GLP-1 franchise with multi-year demand-supply imbalance, a robust pipeline beyond GLP-1 and disciplined capital allocation toward manufacturing capacity.
ARIA's deterministic scorer evaluates LLY across 13 dimensions covering fundamentals, technicals, momentum, volatility, macro and sentiment. Sign up for the live score.
NVO: structural strengths
Co-leadership of the GLP-1 category, a deep diabetes and obesity pipeline including CagriSema and amycretin and a relatively lower valuation multiple than its direct US peer.
ARIA's deterministic scorer evaluates NVO across 13 dimensions covering fundamentals, technicals, momentum, volatility, macro and sentiment. Sign up for the live score.
Risk factors to consider
Risks for LLY
- -GLP-1 multiple is sensitive to insurance coverage and oral-GLP-1 competition.
- -Manufacturing-capacity execution risk.
- -Pricing pressure from Inflation Reduction Act negotiations.
- -Compounding pharmacy and biosimilar exposure long-term.
Risks for NVO
- -Recent CagriSema phase-3 readout disappointed versus expectations.
- -US pricing and formulary access pressure.
- -Manufacturing-capacity execution.
- -Currency exposure as a Danish reporter.
Which is right for you?
The honest answer is "it depends on what kind of investor you are". Both LLY and NVO have credible long-term theses, but they reward different temperaments and different portfolio roles.
If you are a growth investor prioritizing earnings acceleration, the question is which company has the larger ceiling and the cleaner near-term catalysts. Growth investors who want the highest-quality GLP-1 exposure. Investors who want GLP-1 exposure at a more reasonable multiple than Eli Lilly.
If you are a value investor focused on the multiple paid versus the cash returned, look at the P/E and free-cash-flow context in the table above plus the capital-return policy of each name. Where one has a more aggressive buyback or a higher dividend yield, that matters more than headline growth.
If you are a dividend investor concerned with stable income, the qualitative payout discipline of each business is the key signal. Some names on this page pay meaningful dividends with long growth records; others do not pay any dividend at all. Read the risk section carefully to gauge dividend safety, not just yield.
For most readers, the real answer is not "pick one" but "own both, sized to conviction". ARIA's portfolio module can quantify how much of each to hold given your existing portfolio and risk budget.
Get full ARIA analysis on LLY and NVO
See the 5-agent deterministic score (macro, fundamental, technical, sentiment, risk), the ML ensemble probability across four horizons and the Bull vs Bear AI debate for each ticker. Free tier includes three analyses per day, no credit card required.
Per-ticker analysis pages
Frequently asked questions
Is LLY or NVO a better investment right now?+
There is no single right answer. Eli Lilly and (LLY) is generally growth investors who want the highest-quality glp-1 exposure. Novo Nordisk A/S (NVO) is generally investors who want glp-1 exposure at a more reasonable multiple than eli lilly. ARIA Analyst evaluates both with a 5-agent deterministic scoring core (macro, fundamental, technical, sentiment, risk) augmented by AI layers (ML ensemble + Bull vs Bear debate + 10 Deep Search agents); sign up for the live, dated score on each ticker.
What are the main differences between LLY and NVO?+
Eli Lilly and operates in the Drug Manufacturers - General industry within Healthcare; Novo Nordisk A/S operates in the Drug Manufacturers - General industry within Healthcare. Eli Lilly and is positioned for growth investors who want the highest-quality glp-1 exposure. Novo Nordisk A/S is positioned for investors who want glp-1 exposure at a more reasonable multiple than eli lilly.
Which has more growth potential, LLY or NVO?+
Growth potential depends on horizon and risk tolerance. Eli Lilly and's key strength is that best-in-class GLP-1 franchise with multi-year demand-supply imbalance, a robust pipeline beyond GLP-1 and disciplined capital allocation toward manufacturing capacity. Novo Nordisk A/S's key strength is that co-leadership of the GLP-1 category, a deep diabetes and obesity pipeline including CagriSema and amycretin and a relatively lower valuation multiple than its direct US peer. ARIA's ML ensemble produces a calibrated probability for each horizon (1M, 3M, 6M, 12M).
What are the biggest risks for LLY and NVO?+
For Eli Lilly and (LLY), the most-discussed risks include: GLP-1 multiple is sensitive to insurance coverage and oral-GLP-1 competition.; Manufacturing-capacity execution risk.; Pricing pressure from Inflation Reduction Act negotiations.. For Novo Nordisk A/S (NVO), the most-discussed risks include: Recent CagriSema phase-3 readout disappointed versus expectations.; US pricing and formulary access pressure.; Manufacturing-capacity execution..
Does ARIA Analyst recommend LLY or NVO?+
ARIA does not give blanket buy or sell recommendations. Each ticker receives a deterministic multi-agent score, a calibrated ML probability and a Bull vs Bear synthesis. The live scores for LLY and NVO are available to registered users, and they update as the underlying data changes.